SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:DiVA.org:uu-387284"
 

Sökning: onr:"swepub:oai:DiVA.org:uu-387284" > GRFS and CRFS in al...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00009965naa a2200973 4500
001oai:DiVA.org:uu-387284
003SwePub
008190624s2019 | |||||||||||000 ||eng|
009oai:prod.swepub.kib.ki.se:142651924
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-3872842 URI
0247 a https://doi.org/10.1182/bloodadvances.20180301712 DOI
0247 a http://kipublications.ki.se/Default.aspx?queryparsed=id:1426519242 URI
040 a (SwePub)uud (SwePub)ki
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Mehta, Rohtesh S.u Univ Texas MD Anderson Canc Ctr, Dept Stem Cell Transplantat, Div Canc Med, Houston, TX 77030 USA4 aut
2451 0a GRFS and CRFS in alternative donor hematopoietic cell transplantation for pediatric patients with acute leukemia
264 c 2019-05-03
264 1b American Society of Hematology,c 2019
338 a print2 rdacarrier
520 a We report graft-versus-host disease (GVHD)-free relapse-free survival (GRFS) (a composite end point of survival without grade III-IV acute GVHD [aGVHD], systemic therapy-requiring chronic GVHD [cGVHD], or relapse) and cGVHD-free relapse-free survival (CRFS) among pediatric patients with acute leukemia (n = 1613) who underwent transplantation with 1 antigen-mismatched (7/8) bone marrow (BM; n = 172) or umbilical cord blood (UCB; n = 1441). Multivariate analysis was performed using Cox proportional hazards models. To account for multiple testing, P < .01 for the donor/graft variable was considered statistically significant. Clinical characteristics were similar between UCB and 7/8 BM recipients, because most had acute lymphoblastic leukemia (62%), 64% received total body irradiation-based conditioning, and 60% received anti-thymocyte globulin or alemtuzumab. Methotrexate-based GVHD prophylaxis was more common with 7/8 BM (79%) than with UCB (15%), in which mycophenolate mofetil was commonly used. The univariate estimates of GRFS and CRFS were 22% (95% confidence interval [CI], 16-29) and 27% (95% CI, 20-34), respectively, with 7/8 BM and 33% (95% CI, 31-36) and 38% (95% CI, 35-40), respectively, with UCB (P < .001). In multivariate analysis, 7/8 BM vs UCB had similar GRFS (hazard ratio [HR], 1.12; 95% CI, 0.87-1.45; P = .39), CRFS (HR, 1.06; 95% CI, 0.82-1.38; P = .66), overall survival (HR, 1.07; 95% CI, 0.80-1.44; P = .66), and relapse (HR, 1.44; 95% CI, 1.03-2.02; P = .03). However, the 7/8 BM group had a significantly higher risk for grade III-IV aGVHD (HR, 1.70; 95% CI, 1.16-2.48; P = .006) compared with the UCB group. UCB and 7/8 BM groups had similar outcomes, as measured by GRFS and CRFS. However, given the higher risk for grade III-IV aGVHD, UCB might be preferred for patients lacking matched donors.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Hematologi0 (SwePub)302022 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Hematology0 (SwePub)302022 hsv//eng
7001 a Holtan, Shernan G.u Univ Minnesota, Minneapolis, MN USA4 aut
7001 a Wang, Taou Med Coll Wisconsin, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA;Med Coll Wisconsin, Div Biostat, Inst Hlth & Equ, Milwaukee, WI 53226 USA4 aut
7001 a Hemmer, Michael T.u Med Coll Wisconsin, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA4 aut
7001 a Spellman, Stephen R.u Ctr Int Blood & Marrow Transplant Res, Be Match Natl Marrow Donor Program, Minneapolis, MN USA4 aut
7001 a Arora, Muktau Univ Minnesota, Dept Med, Med Ctr, Div Hematol Oncol & Transplantat, Box 736 UMHC, Minneapolis, MN 55455 USA4 aut
7001 a Couriel, Daniel R.u Utah Blood & Marrow Transplant Program, Salt Lake City, UT USA4 aut
7001 a Alousi, Amin M.u Univ Texas MD Anderson Canc Ctr, Dept Stem Cell Transplantat, Div Canc Med, Houston, TX 77030 USA4 aut
7001 a Pidala, Josephu H Lee Moffitt Canc Ctr & Res Inst, Dept Blood & Marrow Transplantat, Tampa, FL USA4 aut
7001 a Abdel-Azim, Hishamu Univ Southern Calif, Keck Sch Med, Childrens Hosp Los Angeles, Transplantat, Los Angeles, CA USA4 aut
7001 a Ahmed, Ibrahimu Childrens Mercy Hosp & Clin, Dept Hematol Oncol & Bone Marrow Transplantat, Kansas City, MO USA4 aut
7001 a Aljurf, Mahmoudu King Faisal Specialist Hosp & Res Ctr, Dept Oncol, Riyadh, Saudi Arabia4 aut
7001 a Askar, Medhatu Baylor Univ, Med Ctr, Dallas, TX USA4 aut
7001 a Auletta, Jeffery J.u Nationwide Childrens Hosp, Div Hematol Oncol Bone Marrow Transplantat, Columbus, OH USA;Nationwide Childrens Hosp, Div Infect Dis, Blood & Marrow Transplant Program, Columbus, OH USA;Nationwide Childrens Hosp, Host Def Program, Columbus, OH USA4 aut
7001 a Bhatt, Vijayau Nebraska Med Ctr, Omaha, NE USA4 aut
7001 a Bredeson, Christopheru Ottawa Hosp, Blood & Marrow Transplant Program, Ottawa, ON, Canada;Ottawa Hosp, Res Inst, Ottawa, ON, Canada4 aut
7001 a Chhabra, Saurabhu Med Coll Wisconsin, Dept Med, Div Hematol Oncol, Milwaukee, WI 53226 USA4 aut
7001 a Gadalla, Shahinazu NCI, Div Canc Epidemiol & Genet, Clin Genet Branch, NIH, Rockville, MD USA4 aut
7001 a Gajewski, Jamesu Oregon Hlth & Sci Univ, Portland, OR 97201 USA4 aut
7001 a Gale, Robert Peteru Imperial Coll London, Hematol Res Ctr, Dept Med, Div Expt Med, London, England4 aut
7001 a Gergis, Usamau New York Presbyterian Hosp, Dept Med Oncol, Hematol Malignancies & Bone Marrow Transplant, Weill Cornell Med Ctr, New York, NY USA4 aut
7001 a Hematti, Peimanu Univ Wisconsin Hosp & Clin, Div Hematol Oncol Bone Marrow Transplantat, Dept Med, Madison, WI 53792 USA4 aut
7001 a Hildebrandt, Gerhard C.u Univ Kentucky, Markey Canc Ctr, Lexington, KY USA4 aut
7001 a Inamoto, Yoshihirou Natl Canc Ctr, Div Hematopoiet Stem Cell Transplantat, Tokyo, Japan4 aut
7001 a Kitko, Carrieu Vanderbilt Univ, Med Ctr, Dept Med, Div Hematol Oncol, Nashville, TN USA4 aut
7001 a Khandelwal, Poojau Cincinnati Childrens Hosp Med Ctr, Dept Pediat, Cincinnati, OH 45229 USA4 aut
7001 a MacMillan, Margaret L.u Univ Minnesota, Blood & Marrow Transplant Program, Minneapolis, MN USA4 aut
7001 a Majhail, Navneetu Cleveland Clin, Blood & Marrow Transplant Program, Taussig Canc Inst, Cleveland, OH 44106 USA4 aut
7001 a Marks, David, Iu Univ Hosp Bristol NHS Trust, Adult Bone Marrow Transplant, Bristol, Avon, England4 aut
7001 a Mehta, Parindau Cincinnati Childrens Hosp Med Ctr, Dept Pediat, Cincinnati, OH 45229 USA4 aut
7001 a Nishihori, Taigau H Lee Moffitt Canc Ctr & Res Inst, Dept Blood & Marrow Transplantat, Tampa, FL USA4 aut
7001 a Olsson, Richardu Karolinska Institutet,Uppsala universitet,Centrum för klinisk forskning i Sörmland (CKFD),Karolinska Inst, Dept Lab Med, Div Therapeut Immunol, Stockholm, Sweden4 aut0 (Swepub:uu)riols677
7001 a Pawarode, Attapholu Univ Michigan, Sch Med, Dept Internal Med, Blood & Marrow Transplantat Program,Div Hematol O, Ann Arbor, MI USA4 aut
7001 a Diaz, Miguel Angelu Hosp Infantil Univ Nino Jesus, Dept Hematol Oncol, Madrid, Spain4 aut
7001 a Prestidge, Timu Starship Childrens Hosp, Blood & Canc Ctr, Auckland, New Zealand4 aut
7001 a Qayed, Munau Emory Univ, Sch Med, Dept Pediat, Atlanta, GA USA4 aut
7001 a Rangarajan, Hemalathau Nationwide Childrens Hosp, Columbus, OH USA4 aut
7001 a Ringden, Olleu Karolinska Institutet4 aut
7001 a Saad, Aymanu Univ Alabama Birmingham, Dept Med, Div Hematol Oncol, Birmingham, AL 35294 USA4 aut
7001 a Savani, Bipin N.u Vanderbilt Univ, Med Ctr, Dept Med, Div Hematol Oncol, Nashville, TN USA4 aut
7001 a Seo, Sachikou Natl Canc Res Ctr East, Dept Hematol & Oncol, Chiba, Japan4 aut
7001 a Shah, Amiu Lucille Packard Childrens Hosp, Stanford Sch Med, Div Stem Cell Transplantat & Regenerat Med, Palo Alto, CA 94304 USA4 aut
7001 a Shah, Niketau Yale New Haven Med Ctr, 20 York St, New Haven, CT 06504 USA4 aut
7001 a Schultz, Kirk R.u Univ British Columbia, British Columbias Childrens Hosp, Dept Pediat Hematol Oncol & Bone Marrow Transplan, Vancouver, BC, Canada4 aut
7001 a Solh, Melhemu Northside Hosp, Blood & Marrow Transplant Grp Georgia, Atlanta, GA USA4 aut
7001 a Spitzer, Thomasu Massachusetts Gen Hosp, Boston, MA 02114 USA4 aut
7001 a Szer, Jeffreyu Royal Melbourne Hosp, Dept Clin Haematol & Bone Marrow Transplantat, Parkville, Vic, Australia4 aut
7001 a Teshima, Takanoriu Kyushu Univ Hosp, Sapporo, Hokkaido, Japan4 aut
7001 a Verdonck, Leo F.u Isala Clin, Dept Hematol Oncol, Zwolle, Netherlands4 aut
7001 a Williams, Kirsten M.u Childrens Natl Hlth Syst, Childrens Res Inst, Washington, DC USA4 aut
7001 a Wirk, Baldeepu Seattle Canc Care Alliance, Div Bone Marrow Transplant, Seattle, WA USA4 aut
7001 a Wagner, Johnu Thomas Jefferson Univ, Dept Med Oncol, Philadelphia, PA 19107 USA4 aut
7001 a Yared, Jean A.u Univ Maryland, Dept Med, Blood & Marrow Transplantat Program, Div Hematol Oncol, Baltimore, MD 21201 USA4 aut
7001 a Weisdorf, Daniel J.u Univ Minnesota, Minneapolis, MN USA4 aut
7102 a Univ Texas MD Anderson Canc Ctr, Dept Stem Cell Transplantat, Div Canc Med, Houston, TX 77030 USAb Univ Minnesota, Minneapolis, MN USA4 org
7730 t Blood Advancesd : American Society of Hematologyg 3:9, s. 1441-1449q 3:9<1441-1449x 2473-9529x 2473-9537
8564 u https://ashpublications.org/bloodadvances/article-pdf/3/9/1441/1631697/advances030171.pdf
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-387284
8564 8u https://doi.org/10.1182/bloodadvances.2018030171
8564 8u http://kipublications.ki.se/Default.aspx?queryparsed=id:142651924

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy